ALLO-501 is under clinical development by Allogene Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ALLO-501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALLO-501 overview
ALLO-501 is under development for the treatment of relapsed and refractory non-Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma or follicular lymphoma. The therapeutic candidate comprises of T cells engineered to express chimeric antigen receptors (CAR T-cells). It acts by targeting cells expressing the CD19 antigen. The therapeutic candidate is developed based on TALEN gene-editing technology.
Allogene Therapeutics overview
Allogene Therapeutics is a clinical-stage biotechnology company that develops allogeneic T-cell (CAR T) therapies for cancer. The company’s pipeline product includes ALLO-501, ALL0-501A, ALL0-316, ALL0-819, ALL0-605 and ALL0-715. Its ALL0-501 and ALL0-501A an off-the-shelf allogeneic CAR T therapy candidates for the treatment of hematological malignancies, CD70 and DLL3 for solid tumors and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics develops products in the therapeutic areas of cancers and solid tumors. It collaborates with other companies for the research and development of immuno-oncology therapies. Allogene Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of ALLO-501’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
